

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Novo Nordisk A/S	08/19/1999
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BIOIMAGE A/S
<b>Street Address:</b>	Morkhoj Bygade 28
<b>City:</b>	Soborg
<b>State/Country:</b>	DENMARK
<b>Postal Code:</b>	DK-2860
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	10947178
<b>CORRESPONDENCE DATA</b>	
Fax Number:	(801)328-1707
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	801.533.9800
Email:	dtangren@wnlaw.com
Correspondent Name:	Dana L. Tangren
Address Line 1:	60 East South Temple
Address Line 2:	1000 Eagle Gate Tower
Address Line 4:	Salt Lake City, UTAH 84103
<b>ATTORNEY DOCKET NUMBER:</b>	16778.2A.1.2
<b>NAME OF SUBMITTER:</b>	Dana L. Tangren
<b>Total Attachments: 2</b>	
source=16778.2a.1 novo to bioimage#page1.tif	
source=16778.2a.1 novo to bioimage#page2.tif	

OP \$40.00 10947178

## ASSIGNMENT

In consideration of the sum of One Dollar and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned

Novo Nordisk A/S  
Novo Allé  
DK-2880 Bagsværd  
Denmark

do hereby declare that we have assigned to

Biolmage A/S  
Mørkhøj Bygade 28  
DK-2860 Søborg  
Denmark

(hereinafter referred to as the ASSIGNEE)

all our rights to

United States Patent Application No. 08/819,612 for the invention entitled

**NOVEL FLUORESCENT PROTEINS**

in and to said United States Patent Application including any and all divisions or continuations thereof and in and to any and all Letters Patent of the United States which may issue on any such application or for said invention, including any and all reissues or extensions thereof, to be held and enjoyed by said ASSIGNEE, its successors, legal representatives and assigns to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by the undersigned had this Assignment not been made.

The undersigned hereby authorizes and requests the Commissioner of Patents and Trademarks to issue any and all Letters Patent of the United States resulting from said application or any division or divisions or continuing or reissue applications thereof to the ASSIGNEE, its successors or assigns in accordance herewith;

The undersigned warrants and covenants that it has the full and unencumbered right to sell and assign the interests herein sold and assigned and that it has not executed and will not execute any document or instrument in conflict herewith;

The undersigned further covenants and agrees that at any time upon request of said ASSIGNEE, its successors, legal representatives or assigns it will communicate to said ASSIGNEE, its successors, legal representatives or assigns all information known to it relating to said invention or patent application and that it will execute and deliver any papers, make all rightful oaths, testify in any legal proceedings and perform all other lawful acts deemed necessary or desirable by said ASSIGNEE, its successors, legal representatives or assigns in order to vest the entire right, title and interest to the said invention, to said application including divisions and continuations thereof and to any and all Letters Patent which may be granted therefor or thereon, including reissues or extensions, in said ASSIGNEE, its successors, or assigns or to assist said ASSIGNEE, its successors, legal representatives or assigns in obtaining, reissuing or enforcing Letters Patent of the United States for said invention.

In witness thereof the parties hereto have executed this assignment as of the day and year stated below.

Place and Date: Bagsvaerd 19/8/99

Novo Nordisk A/S


Signed in accordance with separate Power of Attorney

  
\_\_\_\_\_  
Ulrik Spork  
Director, Corporate Development

/KMe

Place and Date: Bagsvaerd 19/8/99 | Søborg 19/8/99

Biolmage A/S

  
\_\_\_\_\_  
Ulrik Spork  
Director

  
\_\_\_\_\_  
Jørgen Ulrik Vejlsgaard  
Managing Director

PATENT